Formulary
Tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Chronic hepatitis B (initiated by a specialist)**
- **Adult** (By Mouth): 25 mg once daily, for duration of treatment-consult product literature.
**Chronic hepatitis B (initiated by a specialist) for tenofovir alafenamide**
- **Child 12-17 years (body-weight 35 kg and above)** (By mouth): 25 mg once daily, for duration of treatment-consult product literature.
Cautions
Decompensated liver disease; HIV co-infection
Side effects
For all nucleoside reverse transcriptase inhibitors Common or very common Abdominal pain; anaemia (may require transfusion); asthenia; diarrhoea; dizziness; fever; flatulence; headache; insomnia; nausea; neutropenia; skin reactions; vomiting Uncommon Angioedema; pancreatitis Rare or very rare Lactic acidosis Frequency not known Immune reconstitution inflammatory syndrome; osteonecrosis; weight increased Side-effects, further information Osteonecrosis has been reported in patients with advanced HIV disease or following long-term exposure to combination antiretroviral therapy. Side-effects For tenofovir alafenamide Common or very common Abdominal distension; arthralgia Frequency not known Hepatitis aggravated (during or following treatment); nephrotoxicity
Pregnancy
For all nucleoside reverse transcriptase inhibitors Monitoring in pregnancy Mitochondrial dysfunction has been reported in infants exposed to nucleoside reverse transcriptase inhibitors in utero; the main effects include haematological, metabolic, and neurological disorders; all infants whose mothers received nucleoside reverse transcriptase inhibitors during pregnancy should be monitored for relevant signs or symptoms.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
For all nucleoside reverse transcriptase inhibitors In general, manufacturers advise caution in patients with chronic hepatitis B or C (increased risk of hepatic side-effects). Hepatic impairment For tenofovir alafenamide Manufacturer advises caution in decompensated hepatic disease (no information available).
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Tenofovir alafenamide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

